Can Intuitive Surgical Make Up For A Lower Price Per Surgery?
Intuitive Surgical (ISRG) has lost about 12% over the past year, while the S&P 500 returned about 17%. Most of the debate has been about the U.S. procedure growth slowing. The number that should worry a holder more is the money the company collects on the instruments used in each operation. Intuitive plans to lower it.
Intuitive Gets Paid One Surgery At A Time
Intuitive sells surgical robots and then sells the instruments used with them. Instruments and accessories brought in $1.73 billion of the $2.89 billion the company booked in fiscal Q2 2026, close to three fifths of the quarter’s revenue. A da Vinci system is placed once. Its instruments are reordered case after case, so what Intuitive earns per procedure matters more than how many systems it ships.
And In Fiscal Q2 2026 What It Gets Per Surgery Barely Rose
Intuitive collected about $1,830 of instruments and accessories revenue per da Vinci procedure in fiscal Q2 2026, up roughly $30 from the $1,800 reported a year earlier. By comparison, fiscal Q1 2026 revenue per procedure was higher at approximately $1,880 (a $100 year-over-year increase from $1,780). Management attributed the sequential $50 pullback largely to customer ordering patterns, which ran unusually high in the first quarter.
The mix is supposed to be helping. A growing share of da Vinci 5 and SP cases, and wider adoption of force feedback instruments, are each described as accretive. Those tailwinds are already inside that $30.
In 2027 Intuitive Plans To Lower That Number On Purpose
In the first half of 2027 the company expects to increase the number of uses allowed on a subset of its instruments. The purpose is to lower what customers pay per procedure in high-volume benign procedures, and in geographies where cost constraints may be greater. What customers pay per procedure is what Intuitive collects per procedure.
The company has not sized that reduction. It says pricing is still being finalized and it will quantify the program on its next earnings call. Management said the impact lands progressively across 2027, not as a step change. Stapling, energy products and force feedback instruments are excluded from the extended use program.
Intuitive Is Betting More Surgeries Follow
The trade is deliberate: less revenue per case, more cases, and it works only if the cases arrive. In fiscal Q2 2026 US da Vinci procedure growth was 12%, down from 14% in fiscal Q1 2026. Management points to procedures patients can defer and to changes in patient coverage, and says the underlying disease burden is unchanged. Asked how it separates that from a maturing market, management said it is likely both the coverage change and the law of large numbers.
Outside the US, da Vinci procedures grew 20%. Adoption of da Vinci XiR is rising in ambulatory surgery centers in the US and in more cost-constrained countries. Intuitive is not shrinking. Revenue grew 19% in fiscal Q2 2026.
The fear is narrower than a collapse. You are being asked to accept an unquantified cut to part of the line that carries most of the revenue, and to judge how much further ISRG stock can move against you before the size of that cut is known. The right comparison now is against the other stocks that have already fallen.
So Do You Hold ISRG Through 2027?
Perhaps, but only if you are comfortable owning a company that is trading price per case for more cases. And only if you can wait to learn what that trade costs. If you would rather not make a call like that on a single stock, look at the Trefis High Quality Portfolio. That portfolio has a track record of outpacing the three major indices.